肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2015年
3期
218-221
,共4页
沈华%殷先利%刘振洋%李勇%曾毅栋%曾德余%杨晓琳%向芳%周慧俊%李蓉蓉%江少峰%刘武
瀋華%慇先利%劉振洋%李勇%曾毅棟%曾德餘%楊曉琳%嚮芳%週慧俊%李蓉蓉%江少峰%劉武
침화%은선리%류진양%리용%증의동%증덕여%양효림%향방%주혜준%리용용%강소봉%류무
胃癌%D2根治术%辅助化疗%预后
胃癌%D2根治術%輔助化療%預後
위암%D2근치술%보조화료%예후
Gastric cancer%D2 radical gastrectomy%Adjuvant chemotherapy%Prognosis
目的：探讨Ⅱ、Ⅲ期胃癌患者D2根治术后辅助化疗与Ⅱ、Ⅲ期胃癌患者预后的关系。方法将326例行D2根治术的Ⅱ、Ⅲ期胃癌患者按照根治术后是否接受术后辅助化疗、化疗周期数以及化疗方案进行分组，比较各组的5年生存率有无差异。结果全组患者的5年总生存率为52％，化疗组和未化疗组的5年总生存率分别为58％和48％（χ2=2.876，P=0.090）；化疗0周期（组一）、1-3周期（组二）、4周期及以上（组三）的5年生存率依次为48％、49％、68％，整体比较差异无统计学意义（χ2=5.957，P=0.051），仅组一与组三比较差异有统计学意义（χ2=5.908，P=0.015）。辅助化疗患者使用mDCF、FOLFOX和其它方案，3组的5年生存率依次为50％、60％、61％（χ2=0.290，P=0.865）。结论Ⅱ、Ⅲ期胃癌患者在D2根治术后给予不少于4周期的辅助化疗能提高其总生存率，但mDCF、FOLFOX和其它化疗方案之间未见明显差异。
目的：探討Ⅱ、Ⅲ期胃癌患者D2根治術後輔助化療與Ⅱ、Ⅲ期胃癌患者預後的關繫。方法將326例行D2根治術的Ⅱ、Ⅲ期胃癌患者按照根治術後是否接受術後輔助化療、化療週期數以及化療方案進行分組，比較各組的5年生存率有無差異。結果全組患者的5年總生存率為52％，化療組和未化療組的5年總生存率分彆為58％和48％（χ2=2.876，P=0.090）；化療0週期（組一）、1-3週期（組二）、4週期及以上（組三）的5年生存率依次為48％、49％、68％，整體比較差異無統計學意義（χ2=5.957，P=0.051），僅組一與組三比較差異有統計學意義（χ2=5.908，P=0.015）。輔助化療患者使用mDCF、FOLFOX和其它方案，3組的5年生存率依次為50％、60％、61％（χ2=0.290，P=0.865）。結論Ⅱ、Ⅲ期胃癌患者在D2根治術後給予不少于4週期的輔助化療能提高其總生存率，但mDCF、FOLFOX和其它化療方案之間未見明顯差異。
목적：탐토Ⅱ、Ⅲ기위암환자D2근치술후보조화료여Ⅱ、Ⅲ기위암환자예후적관계。방법장326례행D2근치술적Ⅱ、Ⅲ기위암환자안조근치술후시부접수술후보조화료、화료주기수이급화료방안진행분조，비교각조적5년생존솔유무차이。결과전조환자적5년총생존솔위52％，화료조화미화료조적5년총생존솔분별위58％화48％（χ2=2.876，P=0.090）；화료0주기（조일）、1-3주기（조이）、4주기급이상（조삼）적5년생존솔의차위48％、49％、68％，정체비교차이무통계학의의（χ2=5.957，P=0.051），부조일여조삼비교차이유통계학의의（χ2=5.908，P=0.015）。보조화료환자사용mDCF、FOLFOX화기타방안，3조적5년생존솔의차위50％、60％、61％（χ2=0.290，P=0.865）。결론Ⅱ、Ⅲ기위암환자재D2근치술후급여불소우4주기적보조화료능제고기총생존솔，단mDCF、FOLFOX화기타화료방안지간미견명현차이。
Objective To explore the relationship of adjuvant chemotherapy with the prognosis of gastric cancer patients in stageⅡorⅢafter D2 radical gastrectomy. Methods The selected 326 cases of gastric cancer patients in stageⅡorⅢafter D2 radical gas-trectomy were grouped according to their own willingness of chemotherapy, different chemotherapy cycles and regimens. Compare the differences in 5-year survival rate between these groups. Results The 5-year survival rate was 52%for the whole patients. It was 58%and 48%respectively in the chemotherapy group and non-chemotherapy group (χ2=2.876, P=0.090). In the 0 cycle chemotherapy group (group 1), 1-3 cycles group (group 2), and 4 cycles and above group (group 3), the 5-year survival rate was respectively 48%, 49%and 68%. As a whole, there was no statistical differences (χ2=5.957, P=0.051), but the difference between the group 1 and group 3 was statistically significant (χ2=5.908, P=0.015). Adjuvant chemotherapy patients with mDCF, FOLFOX and other solutions had a 5-year survival rate of 50%, 60%and 61%respectively (χ2=0.290, P=0.865). Conclusion Gastric cancer patients in stageⅡorⅢcould have their overall survival improved by getting no less than 4 cycles of adjuvant chemotherapy after D2 radical gastrectomy. But mDCF, FOLFOX and other chemotherapy regimens made no obvious difference in improving overall survival.
